| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0169-409X(01)00200-9 |
| P698 | PubMed publication ID | 11672871 |
| P2093 | author name string | R Herrero-Vanrell | |
| M F Refojo | |||
| P2860 | cites work | Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence | Q47358427 |
| In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2. | Q52903487 | ||
| Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. | Q54257088 | ||
| Microspheres and nanoparticles used in ocular delivery systems | Q58200502 | ||
| The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis | Q66879851 | ||
| Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios | Q67656199 | ||
| Polymers for biodegradable medical devices. VIII. Hydroxybutyrate-hydroxyvalerate copolymers: physical and degradative properties of blends with polycaprolactone | Q68069028 | ||
| Preparation of multi-phase microspheres of poly(D,L-lactic acid) and poly(D,L-lactic-co-glycolic acid) containing a W/O emulsion by a multiple emulsion solvent evaporation technique | Q68136251 | ||
| Experimental intravitreal proliferation and neovascularization in the cynomolgus monkey | Q68952523 | ||
| The development of vitreous membranes and retinal detachment induced by intravitreal carbon microparticles | Q69046788 | ||
| Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres | Q70216445 | ||
| Biomaterials science at a crossroads: are current product liability laws in the United States hampering innovation and the development of safer medical implants? | Q71499820 | ||
| Gamma sterilization of a semi-solid poly(ortho ester) designed for controlled drug delivery--validation and radiation effects | Q72543159 | ||
| Kinetics of a model nucleoside (guanosine) release from biodegradable poly(DL-lactide-co-glycolide) microspheres: a delivery system for long-term intraocular delivery | Q73791991 | ||
| Dexamethasone sustained drug delivery implant for the treatment of severe uveitis | Q74195974 | ||
| Proliferative vitreoretinopathy: an overview | Q77144020 | ||
| Influence of additives on the release profile of nifedipine from poly(DL-lactide-co-glycolide) microspheres | Q77320789 | ||
| The use of additives to modulate the release of a sparingly water soluble drug entrapped in PLA50 microparticles: in vivo investigation | Q93929682 | ||
| Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids | Q33682759 | ||
| New developments in sustained release drug delivery for the treatment of intraocular disease | Q33760311 | ||
| Biomaterials used in the posterior segment of the eye. | Q33860093 | ||
| Determinants of release rate of tetanus vaccine from polyester microspheres. | Q34354937 | ||
| Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties | Q37947040 | ||
| Biodegradable poly(DL-lactic-co-glycolic acid) microspheres containing tetracaine hydrochloride. In-vitro release profile | Q38547370 | ||
| Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits | Q38557085 | ||
| Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure | Q38560910 | ||
| Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres | Q38564886 | ||
| Biodegradable microspheres in drug delivery | Q38565057 | ||
| Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres | Q38568432 | ||
| In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release | Q38569871 | ||
| Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium | Q38573977 | ||
| Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive | Q38580366 | ||
| Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers | Q38595279 | ||
| Microparticulates for ophthalmic drug delivery | Q40764727 | ||
| Biocompatibility issues of implantable drug delivery systems | Q41296005 | ||
| Drainage of Microspheres and RBCs From the Vitreous of Aphakic and Phakic Eyes | Q41667313 | ||
| Phase II results of an intraocular steroid delivery system for cataract surgery | Q41671762 | ||
| Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation | Q41703335 | ||
| Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection | Q41915913 | ||
| Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. | Q42206248 | ||
| Cytomegalovirus retinitis and acquired immunodeficiency syndrome | Q43761529 | ||
| Lactic acid oligomer microspheres containing hydrophilic drugs | Q44071514 | ||
| Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process | Q44188475 | ||
| Gamma irradiation effects on molecular weight and in vitro degradation of poly(D,L-lactide-CO-glycolide) microparticles | Q47352839 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biodegradation | Q696715 |
| drug delivery | Q1392806 | ||
| microsphere | Q1759020 | ||
| biodegradable microsphere | Q125660129 | ||
| P304 | page(s) | 5-16 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Biodegradable microspheres for vitreoretinal drug delivery | |
| P478 | volume | 52 |
| Q38104396 | Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters. |
| Q38904930 | Applications of polymers in intraocular drug delivery systems |
| Q37682216 | Biodegradable intraocular therapies for retinal disorders: progress to date |
| Q43588456 | Biodegradable microspheres of ketorolac tromethamine for parenteral administration |
| Q50455031 | Block copolypeptide nanoparticles for the delivery of ocular therapeutics. |
| Q44451694 | Caco-2 cell culture as a model for famotidine absorption. |
| Q42633090 | Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. |
| Q38217270 | Colloidal drug delivery system: amplify the ocular delivery |
| Q36380667 | Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats. |
| Q37774343 | Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis |
| Q38357497 | Current knowledge on biodegradable microspheres in drug delivery |
| Q36299936 | Delivery of neurotrophic factors and therapeutic proteins for retinal diseases |
| Q42060377 | Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye |
| Q41946889 | Diffusion Regulation in the Vitreous Humor |
| Q36409058 | Drug delivery from ocular implants |
| Q37472106 | Drug delivery systems for the eye. |
| Q30478379 | Drug delivery to the posterior segment of the eye for pharmacologic therapy |
| Q35116140 | Drug delivery to the retina: challenges and opportunities |
| Q59075740 | Effect of gamma irradiation on structural and biological properties of a PLGA-PEG-hydroxyapatite composite |
| Q89002608 | Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema |
| Q58690890 | Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery |
| Q45992838 | Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis. |
| Q33232087 | Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres |
| Q38107200 | Impacts of nanomedicines in ocular pharmacotherapy |
| Q45369102 | In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant |
| Q91990434 | Infusion efficiency of sodium fluorescein into various starches |
| Q26799168 | Intraocular Implants for the Treatment of Autoimmune Uveitis |
| Q37382114 | Intraocular sustained-release delivery systems for triamcinolone acetonide |
| Q41819222 | Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases |
| Q37679951 | Levodopa delivery systems: advancements in delivery of the gold standard |
| Q35262576 | Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. |
| Q37301619 | Modulation of wound healing during and after glaucoma surgery |
| Q38227621 | Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. |
| Q92815426 | Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach |
| Q44601479 | Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation |
| Q39619714 | PEDF in diabetic retinopathy: a protective effect of oxidative stress. |
| Q38987118 | Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases |
| Q90728348 | Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice |
| Q35111354 | Polyhydroxyalkanonate derivatives in current clinical applications and trials |
| Q43083277 | Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study |
| Q37109083 | Safety evaluation of ocular drug delivery formulations: techniques and practical considerations |
| Q47357515 | Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration |
| Q36788228 | Slow-release drug delivery through Elvax 40W to the rat retina: implications for the treatment of chronic conditions. |
| Q35862233 | Strategies to influence PVR development |
| Q35835614 | Sustained release intraocular drug delivery devices for treatment of uveitis |
| Q36894263 | Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications |
| Q30792410 | Synthesis and Properties of Star-Shaped Polylactide Attached to Poly(Amidoamine) Dendrimer |
| Q58784813 | The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy |
| Q52930530 | The use of the vaccinia virus complement control protein (VCP) in the rat retina. |
| Q34291298 | The visualisation of vitreous using surface modified poly(lactic-co-glycolic acid) microparticles |
Search more.